Form 4: Cullinan Therapeutics CFO Mary Kay Fenton Acquires Shares and Stock Options

Cullinan Therapeutics' Chief Financial Officer, Mary Kay Fenton, reports the acquisition of 60,000 shares of common stock and 120,000 stock options.

Summary

• Mary Kay Fenton, the Chief Financial Officer of Cullinan Therapeutics, acquired 60,000 shares of common stock on February 19, 2025.
• These shares were acquired at a price of $0.
• Following this transaction, Ms. Fenton directly owns 60,000 shares of Cullinan Therapeutics' common stock.
• Additionally, Ms. Fenton acquired 120,000 stock options with an exercise price of $9.43 on the same date.
• These options vest over four years, with monthly installments until the fourth anniversary of the grant date, and expire on February 19, 2035.
• After the transaction, Ms. Fenton directly owns 120,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reflecting insider transactions. The acquisition of shares and options by the CFO could be seen as a positive signal, but it's not overwhelmingly so.

Positives

• The acquisition of shares and options by the CFO could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company executives and their confidence in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates the CFO's investment in the company.

Key Dates

Keywords

Cullinan Therapeutics, CGEM, Mary Kay Fenton, Chief Financial Officer, Stock Options, Common Stock, Beneficial Ownership, Form 4, SEC Filing